NCT04757337View on ClinicalTrials.gov

Comparison of Oral Cyclophosphamide vs Doxorubicin in ≥65 Years Old Advanced or Metastatic Soft Tissue Sarcoma Patients

PHASE3RecruitingINTERVENTIONAL

Enrollment

214

Participants

Timeline

Start Date

June 18, 2021

Primary Completion Date

July 31, 2025

Study Completion Date

April 30, 2026

Conditions

Advanced Soft-tissue SarcomaMetastatic Soft-tissue Sarcoma

Interventions

DRUG

Doxorubicin

6 x 3-week cycles corresponding to a maximal duration of 18 weeks

DRUG

Cyclophosphamide

Until progression up to 24 months

Trial Locations (1)

31100

RECRUITING

Institut Claudius Reagaud-IUCT Oncopôle, Toulouse

All Listed Sponsors

lead

UNICANCER

OTHER

NCT04757337 - Comparison of Oral Cyclophosphamide vs Doxorubicin in ≥65 Years Old Advanced or Metastatic Soft Tissue Sarcoma Patients | Biotech Hunter | Biotech Hunter